Home
University of Bergen
Rolf Bjerkvig's picture

Rolf Bjerkvig

Professor
The Department of Biomedicine
researchgate
  • E-mailRolf.Bjerkvig@uib.no
  • Phone+47 55 58 63 52+47 951 18 268
  • Visitor Address
    Jonas Lies vei 91
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen

Rolf Bjerkvig (f. 1953) is Professor for cell biology and has since the ealy 80s worked in experimental cancer biology.

Dr Bjerkvig receives major grants from the Norwegian Research Council, The Norwegian Cancer Society and the European Commission. He is on the editorial board on several international journals and is sitting in several national as well as international funding committees for cancer research in Europe. He has published more than 200 articles in scientific literature and has received a number of research prizes for his work. In 2015, Bjerkvig was awarded the King Olav V Research Prize in Cancer Research.

OD1ANA - Anatomy

MEDOD1, MEDOD2

MEIBM900

FARM260 - Molecular cell biology

BMED330 - intercellular communication

BMED331 - tumor biology

  • Show author(s) (2021). Williams Syndrome Transcription Factor (WSTF) in Brain Tumor Drug Resistance.
  • Show author(s) (2021). TGF-β promotes microtube formation in glioblastoma through thrombospondin 1. Neuro-Oncology. 541-553.
  • Show author(s) (2021). Protocol for derivation of organoids and patient-derived orthotopic xenografts from glioma patient tumors. STAR Protocols.
  • Show author(s) (2021). Novel thioridazine derivates: antiproliferative and apoptosis-inducing activity on glioblastoma cells in vitro get access arrow. Neuro-Oncology. vi170-vi170.
  • Show author(s) (2021). Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1. Acta Neuropathologica. 179-189.
  • Show author(s) (2021). Current landscape and future perspectives in preclinical MR and PET imaging of brain metastasis. Neuro-Oncology Advances (NOA). 14 pages.
  • Show author(s) (2021). A subset of PARP inhibitors induces lethal telomere fusion in ALT-dependent tumor cells. Science Translational Medicine.
  • Show author(s) (2020). Tumor-penetrating peptide for systemic targeting of Tenascin-C. Scientific Reports.
  • Show author(s) (2020). Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology. Acta Neuropathologica. 1-31.
  • Show author(s) (2020). AN1-type zinc finger protein 3 (ZFAND3) is a transcriptional regulator that drives Glioblastoma invasion. Nature Communications.

More information in national current research information system (CRIStin)

1987: Dr. philos. The Gade Institute of Pathology, University of Bergen
1981: M.Sc. Immunology, University of San Francisco, 1981.

Fields of competence 
Cancer research
Human physiology